YOUR ONCOLOGY CRO PARTNER
Move your medicine to market, faster.
As an oncology-focused CRO (contract research organization), TD2 Oncology partners with innovative biotech and pharmaceutical companies to accelerate the development of groundbreaking cancer treatments, ensuring they reach patients as quickly as possible.
As a TD2 Oncology client, you’ll benefit from an integrated suite of tools designed to maximize the success of your research, along with access to a robust patient database that streamlines recruitment efforts.
OUR CAPABILITIES
Support for every research milestone.
Clinical Trial Services
We offer Phase I, II and III clinical trial design, planning and execution utilizing a data-driven, flexible and efficient approach. Using innovative and precise methods for capturing and analyzing data, we identify early signals of response to put your oncology therapy on the path to approval.
Preclinical
In the early phase of oncology research, TD2 sets you up for success with an extensive suite of preclinical tools, over 400 models of cancer as well as extensive knowledge in designing and adapting your study to maximize data value and predict patient response.
Regulatory Support
Your therapy's journey to approval requires a veteran team dedicated to navigating each phase of development. At TD2, we manage the most complex aspects of the regulatory process including IND readiness assessment, program evaluation, IND development and filings, and all FDA interactions.
Flow Cytometry
Gain valuable insights into your drug's therapeutic effects with TD2's high-throughput flow cytometry platform, designed to support diverse assays and cell types. Our advanced immunophenotvping capabilities help uncover vour drug's mechanism of action and pharmacodynamics.
CUTTING-EDGE RESOURCES
Minimize risk during
drug development.
Protect your project against risk and give your new agents the greatest chance of success with our advanced scientific tools built around tumor models, combination strategies and mutational context identification. After all, the future of oncology therapeutic discovery depends on accurately defining the clinical research strategy that will give your treatment an advantage in the clinic and then aligning that strategy with execution.
REGULATORY FILINGS
An impact on modern-day oncology.
Born from the Translational Genomics Research Institute (TGen), TD2 was formed in 2003 as a subsidiary of TGen. Less than two years later, we opened our doors on the campus of the Mayo Clinic in Scottsdale, Arizona. TD2 has helped more than 600 biotech and pharma companies in nearly two decades, maintaining hundreds of client studies per year. Among them, our team has been involved in more than 600 first-in-man major oncology medicines, including numerous clinical trials that have led to approvals in both rare and large indications.
HELPED
MORE THAN
850
biotech and
pharma companies
INVOLVED IN
MORE THAN
850
biotech and
pharma companies
TRANSITIONED
MORE THAN
850
biotech and
pharma companies
